Genotypic and phenotypic classification of cancer: How should the impact of the two diagnostic approaches best be balanced?

Genes Chromosomes and Cancer

Volumn 49, Issue 9, 2010, Pages 763-774

  Brandal, Petter ^a   Teixeira, Manuel R ^b,c,d   Heim, Sverre ^a,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BCR ABL PROTEIN; CCND1 PROTEIN; CYTARABINE; EWSR1 PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IMATINIB; MIXED LINEAGE LEUKEMIA PROTEIN; MYC PROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN; PROTEIN BCL 2; PROTEIN BCL 6; RARA PROTEIN; SS18 PROTEIN; SSX PROTEIN; TRANSCRIPTION FACTOR ETV6; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; BURKITT LYMPHOMA; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GENETICS; CANCER STEM CELL; CARCINOGENESIS; CARCINOMA; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; CYTOLOGY; EPIGENETICS; GENOTYPE; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA; LEUKEMOGENESIS; LOSS OF FUNCTION MUTATION; MOLECULAR GENETICS; MOLECULAR THERAPY; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NEUROECTODERM TUMOR; NONHODGKIN LYMPHOMA; PATHOGENESIS; PHENOTYPE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; REVIEW; RING CHROMOSOME; SARCOMA; SOMATIC MUTATION; TUMOR DIFFERENTIATION; CLASSIFICATION; GENETICS; MUTATION; NEOPLASM; PATHOLOGY;

GENOTYPE; HUMANS; MUTATION; NEOPLASMS; PHENOTYPE;

EID: 77955506634     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20792     Document Type: Review

References (51)

1. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessels JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM. 2002. Response to imatinib mesylate in patients with chronis myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:481-487. (Pubitemid 34879335)
2. Avvisati G, Petti MC, Mandelli F. 1993. What is the best treatment for acute promyelocytic leukemia?Leuk Lymphoma 11:29-35.
3. Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, Beverloo HB, Chang M, Creutzig U, Dworzak MN, Forestier E, Gibson B, Hasle H, Harrison CJ, Heerema NA, Kaspers GJL, Leszl A, Litvinko N, Lo Nigro L, Morimoto A, Perot C, Pieters R, Reinhardt D, Rubnitz JE, Smith FO, Stary J, Stasevich I, Strehl S, Taga T, Tomizawa D, Webb D, Zemanova Z, Zwaan CM, van den Heuvel-Eibrink MM. 2009. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 114:2489-2496.
4. Bentink S, Wessendorf S, Schwaenen C, Rosolowski M, Klapper W, Rosenwald A, Ott G, Banham AH, Berger H, Feller AC, Hansmann ML, Hasenclever D, Hummel M, Lenze D, Möller P, Stuerzenhofecker B, Loeffler M, Truemper L, Stein H, Siebert R, Spang R. 2008. Pathway activation patterns in diffuse large B-cell lymphomas. Leukemia 22:1746-1754.
5. Billing V, Mertens F, Domanski HA, Rydholm A. 2008. Deep-seated ordinary and atypical lipomas: Histopathology, cytogenetics, clinical features, and outcome in 215 tumours of the extremity and trunk wall. J Bone Joint Surg Br 90:929-933. (Pubitemid 352009783)
6. Boerma EG, Siebert R, Kluin PM, Baudis M. 2009. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leukemia 23:225-234.
7. Bohlander SK. 2005. ETV6: A versatile player in leukemogenesis. Semin Cancer Biol 15:162-174.
8. Brandal P, Panagopoulos I, Bjerkehagen B, Gorunova L, Skjeldal S, Micci F, Heim S. 2008. Detection of a t(1;22)(q23;q12) translocation leading to an EWSR1-PBX1 fusion gene in a myoepithelioma. Genes Chromosomes Cancer 47:558-564.
9. Brandal P, Panagopoulos I, Bjerkehagen B, Heim S. 2009. t(19;22)(q13;q12) translocation leading to the novel fusion gene EWSR1-ZNF444 in a myoepithelial carcinoma. Genes Chromosomes Cancer 48:1051-1056.
10. Carroll M, Ohbo-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliand DG, Druker BJ. 1997. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90:4947-4952.
11. Daser A, Rabbitts TH. 2005. The versatile mixed lineage leukemia gene MLL and its many associations in leukaemogenesis. Semin Cancer Biol 15:175-188. (Pubitemid 40501732)
12. Evans HL, Soula EH, Winkelmann RK. 1979. Atypical lipoma, atypical intramuscular lipoma, and well differentiated retroperitoneal liposarcoma: A reappraisal of 30 cases formerly classified as well differentiated liposarcoma. Cancer 43:574-584.
13. Fava C, Cortés JE, Kantarjian H, Jabbour E. 2009. Standard management of patients with chronical myeloid leukemia. Clin Lymphoma Myeloma Suppl 4:S382-S390.
14. Fioretos T, Johansson B. Chronic myeloid leukemia. 2009. In: Heim S, Mitelman F, editors. Cancer Cytogenetics, 3rd ed. New Jersey: Wiley-Blackwell, pp 179-207.
15. Furlan I, Batz C, Flotho C, Mohr B, Lübbert M, Suttorp M, Niemeyer CM. 2009. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood 113:2867-2868.
16. Galili N, Cerny J, Raza A. 2007. Current treatment options: Impact of cytogenetics on the course of myelodysplasia. Curr Treat Options Oncol 8:117-128.
17. Han X, Medeiros LJ, Abruzzo LV, Jones D, Lin P. 2006. Chronic myeloproliferative diseases with the t(5;12)(q33;p13): Clonal evolution is associated with blast crisis. Am J Clin Pathol 125:49-56.
18. Heim S, Mitelman F. 1995. Cancer Cytogenetics, 2nd ed. New York: Wiley-Liss.
19. Heim S, Mitelman F, editors. 2009. Cancer Cytogenetics, 3rd ed. New Jersey: Wiley-Blackwell.
20. Hilden JM, Dinndorf PA, Meerbaum SO, Sather H, Villaluna D, Heerema NA, McGlennen R, Smith FO, Woods WG, Salzer WL, Johnstone HS, Dreyer Z, Reaman GH. 2006. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: Report on CCG 1953 from the Children's Oncology Group. Blood 108:441-451.
21. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Bath TFE, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, Hansmann ML, Haralambieva E, Harder L, Hasenclever D, Kühn M, Lenze D, Lichter P, Martin-Subero JI, Möller P, Müller-Hermelink HK, Ott G, Parwaresch RM, Pott C, Rosenwald A, Rosolowski M, Schwaenen C, Stürzenhofecker B, Szczepanowski M, Trautmann H, Wacker HH, Spang R, Loeffler M, Trümper L, Stein H, Siebert R. 2006. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Eng J Med 354:2419-2430.
22. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. 2001. WHO Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, 3rd ed. Lyon: IARC Press.
23. Johansson B, Harrison C. 2009. Acute myeloid leukemia. In: Heim S, Mitelman F, editors. Cancer Cytogenetics, 3rd ed. New Jersey: Wiley-Blackwell, pp 45-139.
24. Kantarjian H, O'Brien S, Cortes J, Wierda W, Faderl S, Garcia-Manero G, Issa JP, Estey E, Keating M, Freireich EJ. 2008. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 113:1933-1952.
25. Laurini JA, Carter JE. 2010. Gastrointestinal stromal tumors: A review of the literature. Arch Pathol Lab Med 134:134-141.
26. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R. 2006. Lenalidomide in the myelodysplastic syndrome with chromosome 5 deletion. N Engl J Med 355:1456-1465.
27. Lucas DR, Nascimento AG, Sanjay BK, Rock MG. 1994. Well-differentiated liposarcoma. Am J Clin Pathol 102:677-683.
28. Mandahl N, Mertens F. 2009. Soft tissue tumors. In: Heim S, Mitelman F, editors. Cancer Cytogenetics, 3rd ed. New Jersey: Wiley-Blackwell, pp 675-711.
29. Martin-Subero JI, Kreuz M, Bibikova M, Bentink S, Ammerpohl O, Wickham-Garcia E, Rosolowski M, Richter J, Lopez-Serra L, Ballestar E, Berger H, Agirre X, Bernd HW, Calvanese V, Cogliatti SB, Drexler HG, Fan JB, Fraga MF, Hansmann ML, Hummel M, Klapper W, Korn B, Küppers R, MacLeod RAF, Möller P, Ott G, Pott C, Prosper F, Rosenwald A, Schwaenen C, Schübeler D, Seifert M, Stürzenhofecker B, Weber M, Wessendorf S, Loeffler M, Trümper L, Stein H, Spang R, Esteller M, Barker D, Hasenclever D, Siebert R. 2009. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 113:2488-2497.
30. Mentzel T, Fletcher CD. 1995. Lipomatous tumours of soft tissues: An update. Virchows Arch 427:353-363. (Pubitemid 26009607)
31. Mitelman F, Johansson B, Mertens F, editors. 2010. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. Available at: http://cgap.nci.nih.gov/Chromosomes/Mitelman.
32. Möller E, Stenman G, Mandahl N, Hamberg H, Mölne L, van den Oord JJ, Brosjö O, Mertens F, Panagopoulos I. 2008. POU5F1, encoding a key regulator of stem cell pluripotency, is fused to EWSR1 in hidradenoma of the skin and mucoepidermoid carcinoma of the salivary glands. J Pathol 215:78-86.
33. Murphy S, Iland H, Rosenthal D, Laszlo J. 1986. Essential thrombocythemia: An interim report from the polycythemia vera study group. Semin Hematol 23:177-182.
34. Murphy S, Peterson P, Iland H, Laszlo J. 1997. Experience from the polycythemia vera study group: A final report on the diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34:29-39. (Pubitemid 27063140)
35. Niitsu N, Okamoto M, Miura I, Hirano M. 2009. Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma. Cancer Sci 100:233-237.
36. Olney HJ, Le Beau MM. 2009. Myelodysplastic syndromes. In: Heim S, Mitelman F, editors. Cancer Cytogenetics, 3rd ed. New Jersey: Wiley-Blackwell, pp 141-178.
37. Ottman OG, Pfeifer H. 2009. First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults. Curr Opin Oncol 21:S43-S46.
38. Palle J, Frost BM, Forestier E, Gustafsson G, Nygren P, Hellebostad M, Jonsson OG, Kanerva J, Schmiegelow K, Larsson R, Lönnerholm G. 2005. Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage. Br J Haematol 129:189-198.
39. Pellagatti A, Jädersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK, Merup M, Nilsson L, Samuelsson J, Sander B, Wainscoat JS, Boultwood J, Hellström-Lindberg E. 2007. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients. Proc Natl Acad Sci USA 104:11406-11411.
40. Pieters R, Schrappe M, de Lorenzo P, Hann I, de Rossi G, Felice M, Hovi L, LeBlanc T, Szczepanski T, Ferster A, Janka G, Rubnitz J, Silverman L, Stary J, Campbell M, Li CK, Mann G, Suppiah R, Biondi A, Vora A, Valsecchi MG. 2007. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): An observational study and a multicentre randomised trial. Lancet 370:240-250.
41. Pisters PW, Patel SR. 2010. Gastrointestinal stromal tumors: Current management. J Surg Oncol. Published online 8 January 2010.
42. Rice L, Popat U. 2005. Every case of essential thrombocythemia should be tested for the Philadelphia chromosome. Am J Hematol 78:71-73. (Pubitemid 40023752)
43. Rubin BP, Fletcher CD. 1997. The cytogenetics of soft tissue tumours. Histopathology 30:507-511.
44. Rüter B, Wijermans P, Claus R, Kunzmann R, Lübbert. 2007. Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7. Blood 110:1080-1082.
45. Rutkowski P, van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van OOsterom AT, Schuetze SM. 2010. Imatinib mesylat in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 28:1772-1779.
46. Sherbenou DW, Druker BJ. 2007. Applying the discovery of the Philadelphia chromosome. J Clin Invest 117:2067-2074.
47. Studtmann P. 2008. Aristotle's categories. In: Zalta EN, editor. The Stanford Encyclopedia of Philosophy. Fall 2008 Edition. Available at: http://plato.stanford.edu/archives/fall2008/entries/aristotle-categories/.
48. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. 2008. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: IARC Press.
49. Teixeira M. 2006. Recurrent fusion oncogenes in carcinomas. Crit Rev Oncog 12:257-271.
50. Valent P. 2009. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. Blood Rev 23:157-165.
51. Vandenberghe P, Michaux L, Hagemeijer A. 2009. Chronic myeloproliferative neoplasms. In: Heim S, Mitelman F, editors. Cancer Cytogenetics, 3rd ed. New Jersey: Wiley-Blackwell, pp 209-232.